Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Tranquilizing agents, Major --- Antipsychotic Agents --- Schizophrénie --- Schizophrenia --- Physiological aspects --- Chemotherapy --- diagnosis. --- drug therapy. --- therapeutic use. --- Aspect physiologique --- Chimiothérapie

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antipsychotic Agents --- Neuropsychopharmacology --- Tranquilizing drugs --- Neuropsychopharmacologie --- Pharmacodynamics. --- Congresses --- Congresses. --- Congrès --- Antianxiety agents --- Antianxiety drugs --- Anxiolytic agents --- Anxiolytic drugs --- Anxiolytics --- Ataractic drugs --- Minor tranquilizers --- Minor tranquilizing agents --- Minor tranquilizing drugs --- Tranquilizers --- Psychotropic drugs

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book provides clear and concise guidance for clinicians when they encounter a patient with psychosis, starting with the medical work-up to arrive at a diagnosis and ending with the comprehensive care for patients with established schizophrenia. It covers the optimal use of medications (emphasizing safe use) but also addresses other treatment approaches (psychological treatments, rehabilitation) and the larger societal context of care, including how to work effectively in complex systems. It uniquely condenses the literature into teaching points without simplifying too much, effectively serving as a learning tool for trainees and professionals. For this second edition, the book was extensively updated and its content expanded, with new figures as well. Each chapter begins with an initial summary and includes Tips and Key Points in text boxes. Each chapter also includes links to external websites and additional readings. The book contains clinical and practical wisdom for clinicians who are treating real patients at the front lines, setting it apart from all other texts. Psychotic Disorders is an excellent resource for medical students, early career professionals such as trainees and fellows, and related clinicians seeking additional training and resources, including those in psychiatry, psychology, neurology, and all others.

Schizophrenia --- Antipsychotic drugs --- Diagnosis. --- Therapy. --- Therapeutic use. --- Antipsychotic agents --- Antipsychotics --- Major tranquilizers --- Major tranquilizing agents --- Major tranquilizing drugs --- Neuroleptic agents --- Neuroleptic drugs --- Neuroleptics --- Neurolepts --- Tranquilizing drugs, Major --- Psychotropic drugs --- Psychoses --- Dementia praecox --- Schizophrenic disorders --- Schizotypal personality disorder --- Chemotherapy --- Psychiatry. --- Medicine and psychology --- Mental health --- Psychology, Pathological

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical  needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all.  Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.

Antipsychotic agents -- Therapeutic use. --- Antipsychotic drugs -- Controlled release. --- Injections. --- Antipsychotic drugs --- Tranquilizing Agents --- Schizophrenia and Disorders with Psychotic Features --- Therapeutics --- Psychotropic Drugs --- Central Nervous System Depressants --- Mental Disorders --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Central Nervous System Agents --- Physiological Effects of Drugs --- Psychiatry and Psychology --- Pharmacologic Actions --- Therapeutic Uses --- Chemical Actions and Uses --- Chemicals and Drugs --- Antipsychotic Agents --- Drug Therapy --- Psychotic Disorders --- Health & Biological Sciences --- Pharmacy, Therapeutics, & Pharmacology --- Antipsychotic drugs. --- Antipsychotic agents --- Antipsychotics --- Major tranquilizers --- Major tranquilizing agents --- Major tranquilizing drugs --- Neuroleptic agents --- Neuroleptic drugs --- Neuroleptics --- Neurolepts --- Tranquilizing drugs, Major --- Medicine. --- Pharmacy. --- Neurosciences. --- Pharmacology. --- Behavioral sciences. --- Proteins. --- Neurobiology. --- Biomedicine. --- Pharmacology/Toxicology. --- Receptors. --- Behavioral Sciences. --- Psychotropic drugs --- Psychoses --- Chemotherapy --- Toxicology. --- Cell receptors. --- Animal behavior. --- Chemistry --- Medicine --- Drugs --- Materia medica --- Pharmacology --- Animals --- Animals, Habits and behavior of --- Behavior, Animal --- Ethology --- Animal psychology --- Zoology --- Ethologists --- Psychology, Comparative --- Neurosciences --- Cell membrane receptors --- Cell surface receptors --- Receptors, Cell --- Binding sites (Biochemistry) --- Cell membranes --- Proteins --- Neural sciences --- Neurological sciences --- Neuroscience --- Medical sciences --- Nervous system --- Chemicals --- Poisoning --- Poisons --- Behavior --- Toxicology --- Proteins . --- Proteids --- Biomolecules --- Polypeptides --- Proteomics --- Drug effects --- Medical pharmacology --- Pharmacy --- Physiological effect

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Continuous rigorous research in basic neurosciences and in clinical studies has enormously increased our knowledge of the neurobiological basis of mental functions and of the neuronal dysfunctions underlying such diseases as schizophrenia, depression, attention deficit disorder, and Parkinson's disease. A transmitter system does not work in isolation, it interacts with other transmitters and the balance between several transmitter determines the outcome, either physiological or pathological. Such a critical balance exists between dopamine and glutamate, which in many brain areas play functionally opposing roles. In Dopamine and Glutamate in Psychiatric Disorders, a panel of neurochemists, pharmacologists, experimental psychologists, and clinicians summarizes our current understanding of the interactive role of dopamine and glutamate in psychiatric diseases and from that develops novel therapeutic strategies and possibilities for the future. Among the new ideas presented are hypotheses on the role of dopamine and glutamate in aggression, the glutamate system in anxiety disorders, glutamate and neurodegeneration, on the origin, progression, and cognitive aspects of Parkinson's disease. Additional chapters offer illuminating insights into a variety of psychiatric diseases, including attention deficit hyperactivity disorder, stress, aggression, addiction, schizophrenia, depression, social phobias, dementias, bulimia, and neurodegenerative diseases like Parkinson's and Alzheimer's diseases. Each chapter summarizes the prevalence and symptoms of the disease and explains the involvement of dopamine and/or glutamate systems using the newer molecular approaches such as transgenic knockout or knockin mice and recent brain imaging techniques. The authors also offer a critical selection and evaluation of relevant literature and a description of future directions for new therapy development. Path-breaking and insightful, Dopamine and Glutamate in Psychiatric Disorders offers behavioral pharmacologists, neurobiologists, and clinicians an enlightening review of the neurobiological basis and treatment strategies of today's most important psychiatric and neurological diseases.

Medicine & Public Health. --- Psychiatry. --- Medicine. --- Médecine --- Psychiatrie --- Antidepressive Agents -- pharmacology. --- Antipsychotic Agents -- pharmacology. --- Dopamine -- Pathophysiology. --- Glutamate -- Pathophysiology. --- Mental Disorders -- drug therapy. --- Mental Disorders -- etiology. --- Nervous System Diseases -- drug therapy. --- Nervous System Diseases -- etiology. --- Neuropsychiatry. --- Neurotransmitter receptors. --- Neuropsychiatry --- Dopamine --- Glutamate --- Neurotransmitter receptors --- Tranquilizing Agents --- Receptors, Catecholamine --- Amino Acids, Dicarboxylic --- Psychiatry and Psychology --- Psychotropic Drugs --- Excitatory Amino Acids --- Receptors, Amino Acid --- Diseases --- Amino Acids, Acidic --- Catecholamines --- Central Nervous System Agents --- Amino Acids --- Receptors, Biogenic Amine --- Central Nervous System Depressants --- Biogenic Monoamines --- Receptors, Neurotransmitter --- Receptors, G-Protein-Coupled --- Amines --- Amino Acids, Peptides, and Proteins --- Receptors, Cell Surface --- Biogenic Amines --- Organic Chemicals --- Physiological Effects of Drugs --- Therapeutic Uses --- Pharmacologic Actions --- Membrane Proteins --- Chemicals and Drugs --- Proteins --- Chemical Actions and Uses --- Antidepressive Agents --- Antipsychotic Agents --- Mental Disorders --- Glutamic Acid --- Receptors, Dopamine --- Receptors, Glutamate --- Nervous System Diseases --- Medicine --- Psychiatry --- Health & Biological Sciences --- Neurology --- Psychiatry - General --- Pathophysiology --- Glutamic acid --- Pathophysiology. --- Behavioral neurology --- Medicine and psychology --- Mental health --- Psychology, Pathological --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Excitatory amino acids --- Umami (Taste) --- Biogenic amines --- Bromocriptine --- Neurotransmitters --- Biological psychiatry --- Cell receptors --- Hormone receptors --- Neural receptors